Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07403812 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assessing DCog Short for Neurotoxicity in CAR-T

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 1 month later Aug 31, 2026 → Sep 30, 2027
See other at-risk trials from Beth Israel Deaconess Medical Center

Record History

  1. Primary completion pushed from Aug 31, 2026 to Sep 30, 2027 Recruitment opened · Completion pushed from Aug 31, 2027 to Aug 31, 2028 · Start date changed from estimate of Jul 2026 to Apr 13, 2026 · 3 more Show 6 more changesShow less
    • Recruitment opened
    • Completion pushed from Aug 31, 2027 to Aug 31, 2028
    • Start date changed from estimate of Jul 2026 to Apr 13, 2026
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.
Trial Details
NCT Number NCT07403812
Lead Sponsor Beth Israel Deaconess Medical Center
Conditions Neurotoxicity, Neurotoxicity Syndromes, Hematologic Malignancy, Immune Effector Cell Associated Neurotoxicity Syndrome
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov